Lexiscan, Rapiscan(regadenoson)
Lexiscan, Rapiscan (regadenoson) is a small molecule pharmaceutical. Regadenoson was first approved as Lexiscan on 2008-04-10. It has been approved in Europe to treat myocardial perfusion imaging. The pharmaceutical is active against adenosine receptor A2a. In addition, it is known to target adenosine receptor A2b, adenosine receptor A3, and adenosine receptor A1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| diagnosis | D003933 |
Trade Name
FDA
EMA
Lexiscan (generic drugs available since 2022-04-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Regadenoson
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEXISCAN | Astellas Pharma | N-022161 RX | 2008-04-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lexiscan(r) (regadenoson) | New Drug Application | 2020-02-22 |
| regadenoson | ANDA | 2022-02-02 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2785 | Injection, regadenoson, 0.1 mg |
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | 3 | 6 | 6 | 7 | 12 | 33 | |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 2 | 2 | — | 1 | 1 | 5 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | 1 | — | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | 1 | — | 2 |
| Coronary disease | D003327 | — | — | — | 1 | 1 | 2 | ||
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | — | — | 1 | — | 1 |
| Heart transplantation | D016027 | EFO_0010673 | — | — | — | 1 | — | 1 | |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 1 | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 2 | — | — | 1 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | — | — | — | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | U07.1 | 1 | 1 | — | — | — | 1 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Retinal artery occlusion | D015356 | EFO_1001154 | H34.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Magnetic resonance imaging | D008279 | 1 | — | — | — | 1 | 2 | ||
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 | |
| Astrocytoma | D001254 | EFO_0000271 | 1 | — | — | — | — | 1 | |
| Oligodendroglioma | D009837 | EFO_0000631 | 1 | — | — | — | — | 1 | |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
| Left ventricular dysfunction | D018487 | — | — | — | — | 1 | 1 | ||
| Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | 1 | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | REGADENOSON |
| INN | regadenoson |
| Description | Regadenoson is a purine nucleoside. |
| Classification | Small molecule |
| Drug class | adenosine A receptor agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O |
Identifiers
| PDB | — |
| CAS-ID | 313348-27-5 |
| RxCUI | 1546015 |
| ChEMBL ID | CHEMBL3989695 |
| ChEBI ID | — |
| PubChem CID | 219024 |
| DrugBank | DB06213 |
| UNII ID | 7AXV542LZ4 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,427 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,900 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more